BR112018071216A2 - inibidores de bromodomínios - Google Patents
inibidores de bromodomíniosInfo
- Publication number
- BR112018071216A2 BR112018071216A2 BR112018071216A BR112018071216A BR112018071216A2 BR 112018071216 A2 BR112018071216 A2 BR 112018071216A2 BR 112018071216 A BR112018071216 A BR 112018071216A BR 112018071216 A BR112018071216 A BR 112018071216A BR 112018071216 A2 BR112018071216 A2 BR 112018071216A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- bromodomain inhibitors
- compounds
- diseases
- aids
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title 1
- 108050009021 Bromodomains Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
a presente invenção proporciona compostos de fórmula (i) (i) em que r1, r2, r3, r4, r6, x1 e x2 têm quaisquer dos valores definidos no relatório descritivo, e seus sais farmaceuticamente aceitáveis, que são úteis como agentes no tratamento de doenças e estados clínicos, incluindo doenças inflamatórias, câncer e sida. também são proporcionadas composições farmacêuticas compreendendo compostos de fórmula (i).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016079362 | 2016-04-15 | ||
PCT/CN2017/080511 WO2017177955A1 (en) | 2016-04-15 | 2017-04-14 | Bromodomain inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018071216A2 true BR112018071216A2 (pt) | 2019-02-05 |
Family
ID=60042835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018071216A BR112018071216A2 (pt) | 2016-04-15 | 2017-04-14 | inibidores de bromodomínios |
Country Status (38)
Country | Link |
---|---|
US (3) | US10633379B2 (pt) |
EP (2) | EP3693369A3 (pt) |
JP (2) | JP6978424B2 (pt) |
KR (1) | KR102250415B1 (pt) |
CN (1) | CN109071534B (pt) |
AR (1) | AR108207A1 (pt) |
AU (2) | AU2017251537B2 (pt) |
BR (1) | BR112018071216A2 (pt) |
CA (1) | CA3018802A1 (pt) |
CL (1) | CL2018002924A1 (pt) |
CO (1) | CO2018011064A2 (pt) |
CR (1) | CR20180541A (pt) |
CY (1) | CY1123025T1 (pt) |
DK (1) | DK3442972T3 (pt) |
DO (1) | DOP2018000227A (pt) |
EC (1) | ECSP18083519A (pt) |
ES (1) | ES2793239T3 (pt) |
HR (1) | HRP20200728T1 (pt) |
HU (1) | HUE050217T2 (pt) |
IL (1) | IL261586B (pt) |
LT (1) | LT3442972T (pt) |
MA (2) | MA44674B1 (pt) |
MD (1) | MD3442972T2 (pt) |
ME (1) | ME03759B (pt) |
MX (1) | MX2018012541A (pt) |
MY (1) | MY190795A (pt) |
PE (1) | PE20190472A1 (pt) |
PH (1) | PH12018501920A1 (pt) |
PL (1) | PL3442972T3 (pt) |
PT (1) | PT3442972T (pt) |
RS (1) | RS60302B1 (pt) |
RU (1) | RU2741808C2 (pt) |
SG (1) | SG11201808003RA (pt) |
SI (1) | SI3442972T1 (pt) |
TW (3) | TWI704147B (pt) |
UA (1) | UA124764C2 (pt) |
UY (1) | UY37205A (pt) |
WO (1) | WO2017177955A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA124764C2 (uk) * | 2016-04-15 | 2021-11-17 | Еббві Інк. | Інгібітори бромодомену |
AU2016426480A1 (en) * | 2016-10-14 | 2019-04-18 | Abbvie Inc. | Bromodomain inhibitors |
JP2020517618A (ja) | 2017-04-21 | 2020-06-18 | エピザイム,インコーポレイティド | Ehmt2阻害剤との併用療法 |
CA3106733A1 (en) | 2018-07-25 | 2020-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
WO2020063976A1 (zh) * | 2018-09-29 | 2020-04-02 | 如东凌达生物医药科技有限公司 | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 |
CN113226322A (zh) | 2018-10-30 | 2021-08-06 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
JP2022529575A (ja) * | 2019-03-17 | 2022-06-23 | シャンハイ リンジーン バイオファーマ カンパニー リミテッド | ピロールアミドピリドン系化合物、製造方法及び使用 |
GB201905721D0 (en) * | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
WO2020232214A1 (en) * | 2019-05-14 | 2020-11-19 | Abbvie Inc. | Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor |
EP3997070A4 (en) | 2019-07-02 | 2023-07-26 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS |
CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
CN115667254A (zh) * | 2020-05-21 | 2023-01-31 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
WO2022116968A1 (zh) * | 2020-12-01 | 2022-06-09 | 成都苑东生物制药股份有限公司 | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 |
WO2022228421A1 (zh) * | 2021-04-30 | 2022-11-03 | 成都苑东生物制药股份有限公司 | 一种新型brd4溴结构域protac蛋白降解剂、其制备方法及医药用途 |
WO2023275542A1 (en) | 2021-06-29 | 2023-01-05 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
CN115611890B (zh) * | 2021-07-15 | 2024-05-31 | 成都硕德药业有限公司 | 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途 |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1507957A (en) | 1975-03-25 | 1978-04-19 | Byk Gulden Lomberg Chem Fab | Nitrofuryl-pyrazole derivatives methods for producing them and medicaments comprising them |
US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
US4004012A (en) | 1975-10-14 | 1977-01-18 | Sterling Drug Inc. | 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones |
DE2845456A1 (de) | 1978-10-19 | 1980-08-14 | Merck Patent Gmbh | 6-arylpyridazin-3-one und verfahren zu ihrer herstellung |
US4298609A (en) | 1979-08-30 | 1981-11-03 | Sterling Drug Inc. | 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents |
FR2478640A1 (fr) | 1980-03-24 | 1981-09-25 | Sanofi Sa | Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique |
US4486431A (en) | 1981-01-14 | 1984-12-04 | Sterling Drug Inc. | Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones |
US4305943A (en) | 1980-04-28 | 1981-12-15 | Sterling Drug Inc. | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics |
US4304776A (en) | 1980-04-28 | 1981-12-08 | Sterling Drug Inc. | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics |
US4346221A (en) | 1980-04-28 | 1982-08-24 | Sterling Drug Inc. | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones |
US4337253A (en) | 1980-04-28 | 1982-06-29 | Sterling Drug Inc. | 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic |
US4338446A (en) | 1980-04-28 | 1982-07-06 | Sterling Drug Inc. | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates |
US4559352A (en) | 1981-03-30 | 1985-12-17 | Sterling Drug Inc. | 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof |
US4404203A (en) | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
US4515797A (en) | 1981-09-08 | 1985-05-07 | Sterling Drug Inc. | 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof |
US4465686A (en) | 1981-09-08 | 1984-08-14 | Sterling Drug Inc. | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation |
US4353905A (en) | 1981-09-17 | 1982-10-12 | Warner-Lambert Company | Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones |
US4599423A (en) | 1982-04-26 | 1986-07-08 | Sterling Drug Inc. | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones |
US4734415A (en) | 1982-08-13 | 1988-03-29 | Warner-Lambert Company | Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones |
DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
DE3321012A1 (de) | 1983-06-10 | 1984-12-13 | A. Nattermann & Cie GmbH, 5000 Köln | Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung |
US4666902A (en) | 1983-06-20 | 1987-05-19 | Cassella Aktiengesellschaft | Tetrahydropyridazinone derivatives, processes for their preparation and their use |
GB8323553D0 (en) | 1983-09-02 | 1983-10-05 | Smith Kline French Lab | Pharmaceutical compositions |
US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
US5192563A (en) | 1986-10-22 | 1993-03-09 | Wm. Wrigley, Jr. Company | Strongly mint-flavored chewing gums with reduced bitterness and harshness |
US5221543A (en) | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
US4863745A (en) | 1986-10-22 | 1989-09-05 | Wm. Wrigley Jr. Company | Chewing gum containing zein coated high-potency sweetener and method |
US5112625A (en) | 1989-02-15 | 1992-05-12 | Wm. Wrigley Jr. Company | Aqueous zein coated sweeteners and other ingredients for chewing gum |
US5217735A (en) | 1986-10-22 | 1993-06-08 | Wm. Wrigley Jr. Company | Method of making chewing gum with delayed release ingredients |
US4908371A (en) | 1987-11-10 | 1990-03-13 | Ciba-Geigy Corporation | Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload |
US4919941A (en) | 1987-12-18 | 1990-04-24 | Wm. Wrigley Jr. Company | Chewing gum containing delayed release protein sweetener and method |
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
WO1991012251A1 (en) | 1990-02-19 | 1991-08-22 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE69131268T2 (de) | 1990-09-21 | 1999-12-30 | Rohm & Haas | Dihydropyridazinone und Pyridazinone als Fungizide |
WO1992006087A1 (fr) | 1990-10-02 | 1992-04-16 | Kaken Pharmaceutical Co., Ltd. | Derive d'ethynylphenyle a substitution pyridazinone et medicament contre les affections des organes circulatoires contenant ce derive en tant qu'ingredient actif |
DE4127404A1 (de) | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CN1038249C (zh) | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
WO1993007146A1 (en) | 1991-10-09 | 1993-04-15 | Syntex (U.S.A.) Inc. | Benzo and pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity |
US5716954A (en) | 1991-10-09 | 1998-02-10 | Syntex U.S.A. Inc. | Benzopyridazinone and pyridopyridazinone compounds |
DE4237656A1 (de) | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
US5668279A (en) | 1992-11-02 | 1997-09-16 | Merck & Co., Inc. | Substituted phthalazinones as neurotensin antagonists |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
TW263498B (pt) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
JP3247540B2 (ja) | 1994-05-12 | 2002-01-15 | 株式会社日立製作所 | パケット化通信装置および切替え装置 |
US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
JPH08337583A (ja) | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
JPH11508267A (ja) | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
AU723064B2 (en) | 1995-08-25 | 2000-08-17 | Dow Agrosciences Llc | Compositions having synergistic fungitoxic effects |
WO1999029695A1 (en) | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
KR100338144B1 (ko) | 1996-09-13 | 2002-05-24 | 가마쿠라 아키오 | 티에노트리아졸로디아제핀 화합물 및 그의 약제학적 용도 |
US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
US6143751A (en) | 1997-04-01 | 2000-11-07 | Astrazeneca Uk Limited | Pyridine derivatives and pharmaceutical compositions containing them |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
CN1142148C (zh) | 1997-11-19 | 2004-03-17 | 兴和株式会社 | 新颖的哒嗪衍生物和含有其作为有效成分的药物 |
EP0934933A1 (en) | 1998-02-06 | 1999-08-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phthalazinones |
TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
CN1146561C (zh) | 1998-07-16 | 2004-04-21 | 盐野义制药株式会社 | 具有抗肿瘤活性的嘧啶衍生物 |
US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
CN1297916A (zh) | 1999-11-26 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸 |
DE10010423A1 (de) | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung |
CN1315397A (zh) | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸 |
ATE388621T1 (de) | 2000-07-04 | 2008-03-15 | Robert John Eyre | Erntemaschine |
US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
JP2003313169A (ja) | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | 4,4−ジフルオロ−3−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
CA2529790A1 (en) | 2003-06-27 | 2005-01-27 | Banyu Pharmaceutical Co., Ltd. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
AU2004263148B2 (en) | 2003-08-06 | 2008-08-21 | Vertex Pharmaceuticals, Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
JP2007509149A (ja) | 2003-10-20 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なヒドロキシピリドピロロピラジンジオン化合物 |
SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
CA2579087C (en) * | 2004-09-03 | 2012-05-01 | Yuhan Corporation | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
CA2588949A1 (en) | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
AU2005310467B2 (en) | 2004-12-01 | 2011-06-23 | Msd K.K. | Substituted pyridone derivative |
US7994325B2 (en) | 2005-03-14 | 2011-08-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US20060276496A1 (en) | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
WO2006112331A1 (ja) | 2005-04-13 | 2006-10-26 | Dainippon Simitomo Pharma Co., Ltd. | 新規縮合ピロール誘導体 |
EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
WO2007008144A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
WO2007008145A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
JP5324785B2 (ja) | 2005-10-28 | 2013-10-23 | 武田薬品工業株式会社 | 複素環アミド化合物及びその用途 |
KR20080080173A (ko) | 2005-12-14 | 2008-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클 |
US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
MY148634A (en) | 2006-07-25 | 2013-05-15 | Cephalon Inc | Pyridazinone derivatives |
WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CN101605797A (zh) | 2006-11-13 | 2009-12-16 | 伊莱利利公司 | 治疗炎症疾病和癌症的噻吩并嘧啶酮 |
WO2008133669A2 (en) | 2006-12-14 | 2008-11-06 | Gilead Sciences, Inc. | Viral inhibitors |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
WO2008148034A1 (en) | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
WO2009017671A1 (en) | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
SG185330A1 (en) | 2007-10-23 | 2012-11-29 | Hoffmann La Roche | Novel kinase inhibitors |
WO2009054790A1 (en) | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
JP5451752B2 (ja) | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
WO2009134387A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
TW200946520A (en) | 2008-05-01 | 2009-11-16 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
CA2730499A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2010019210A2 (en) | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
JP5102397B2 (ja) | 2008-11-20 | 2012-12-19 | メルク・シャープ・エンド・ドーム・コーポレイション | アリールメチルベンゾキナゾリノンm1レセプターポジティブアロステリックモジュレーター |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
GEP20156309B (en) | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
ES2564318T3 (es) | 2009-11-05 | 2016-03-21 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
WO2011054553A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
CN102666774A (zh) | 2009-11-11 | 2012-09-12 | 纳幕尔杜邦公司 | 在次级回路制冷系统中的制冷剂储存 |
WO2011133722A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
PL2571503T3 (pl) | 2010-05-14 | 2015-06-30 | Dana Farber Cancer Inst Inc | Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń |
WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013086357A2 (en) | 2011-12-07 | 2013-06-13 | Affectiva, Inc. | Affect based evaluation of advertisement effectiveness |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US20130188311A1 (en) | 2012-01-23 | 2013-07-25 | International Business Machines Corporation | Cooling and noise-reduction apparatus |
CN104334526A (zh) | 2012-04-20 | 2015-02-04 | 艾伯维公司 | 异吲哚酮衍生物 |
MX2014015156A (es) | 2012-06-12 | 2015-08-06 | Abbvie Inc | Derivados de piridinona y piridazinona. |
KR102008733B1 (ko) | 2012-06-15 | 2019-08-09 | 소프트 머신즈, 인크. | 스토어 상위 서열에 기초하여 상이한 스레드들로부터의 포워딩을 구현하는 스레드에 무관한 로드 스토어 버퍼 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
MX2015012005A (es) | 2013-03-11 | 2016-04-04 | Abbvie Inc | Inhibidores de bromodominio. |
MX2015012158A (es) | 2013-03-11 | 2015-12-01 | Abbvie Inc | Inhibidores de bomodominio tetraciclicos fusionados. |
KR102224992B1 (ko) | 2013-03-12 | 2021-03-10 | 애브비 인코포레이티드 | 테트라사이클릭 브로모도메인 억제제 |
EP2970276A1 (en) | 2013-03-12 | 2016-01-20 | AbbVie Inc. | Dihydro-pyrrolopyridinone bromodomain inhibitors |
BR112015022551A2 (pt) | 2013-03-12 | 2017-07-18 | Abbvie Inc | inibidores de amido pirrol |
RU2016102647A (ru) | 2013-06-28 | 2017-08-01 | Эббви Инк. | Ингибиторы бромодомена |
AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
CN103387576A (zh) * | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
CN108558889B (zh) * | 2013-10-18 | 2021-11-05 | 赛尔基因昆蒂赛尔研究公司 | 布罗莫结构域抑制剂 |
US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
US9428514B2 (en) | 2013-12-09 | 2016-08-30 | Abbvie Inc. | Bromodomain inhibitors |
JP2016539990A (ja) | 2013-12-10 | 2016-12-22 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害薬 |
UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US10174024B2 (en) | 2015-05-12 | 2019-01-08 | Bristol-Myers Squibb Company | 5H-pyrido[3,2-B]indole compounds as anticancer agents |
JP6606444B2 (ja) | 2016-03-10 | 2019-11-13 | 株式会社Subaru | 車両用制御装置 |
SI3442947T1 (sl) | 2016-04-15 | 2023-10-30 | Epizyme, Inc. | Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2 |
CA3019009A1 (en) | 2016-04-15 | 2017-10-19 | Syngenta Participations Ag | Herbicidal pyridazinone compounds |
FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
UA124764C2 (uk) * | 2016-04-15 | 2021-11-17 | Еббві Інк. | Інгібітори бромодомену |
AU2017251155B2 (en) | 2016-04-15 | 2021-08-05 | Bayer Animal Health Gmbh | Pyrazolopyrimidine derivatives |
AR109250A1 (es) | 2016-06-09 | 2018-11-14 | Acetylon Pharmaceuticals Inc | Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet |
WO2017216772A2 (en) | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
WO2017223268A1 (en) | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
AU2016426480A1 (en) | 2016-10-14 | 2019-04-18 | Abbvie Inc. | Bromodomain inhibitors |
US20200048220A1 (en) | 2016-10-14 | 2020-02-13 | Abbvie Inc. | Bromodomain Inhibitors |
WO2018095933A1 (en) | 2016-11-22 | 2018-05-31 | Université D'aix-Marseille (Amu) | Method of prognosticating, or for determining the efficiency of a compound for treating cancer |
WO2018130174A1 (zh) | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
WO2018188047A1 (en) | 2017-04-14 | 2018-10-18 | Abbvie Inc. | Bromodomain inhibitors |
WO2018223909A1 (zh) | 2017-06-05 | 2018-12-13 | 成都海创药业有限公司 | 一种嵌合分子及其制备和应用 |
CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
-
2017
- 2017-04-14 UA UAA201811188A patent/UA124764C2/uk unknown
- 2017-04-14 SG SG11201808003RA patent/SG11201808003RA/en unknown
- 2017-04-14 PE PE2018001988A patent/PE20190472A1/es unknown
- 2017-04-14 MA MA44674A patent/MA44674B1/fr unknown
- 2017-04-14 MX MX2018012541A patent/MX2018012541A/es unknown
- 2017-04-14 SI SI201730258T patent/SI3442972T1/sl unknown
- 2017-04-14 CR CR20180541A patent/CR20180541A/es unknown
- 2017-04-14 WO PCT/CN2017/080511 patent/WO2017177955A1/en active Application Filing
- 2017-04-14 MD MDE20190228T patent/MD3442972T2/ro unknown
- 2017-04-14 PL PL17781931T patent/PL3442972T3/pl unknown
- 2017-04-14 US US16/093,483 patent/US10633379B2/en active Active
- 2017-04-14 TW TW106112643A patent/TWI704147B/zh active
- 2017-04-14 TW TW109127958A patent/TWI764237B/zh active
- 2017-04-14 BR BR112018071216A patent/BR112018071216A2/pt active Search and Examination
- 2017-04-14 CA CA3018802A patent/CA3018802A1/en active Pending
- 2017-04-14 MY MYPI2018703563A patent/MY190795A/en unknown
- 2017-04-14 LT LTEP17781931.5T patent/LT3442972T/lt unknown
- 2017-04-14 AU AU2017251537A patent/AU2017251537B2/en active Active
- 2017-04-14 PT PT177819315T patent/PT3442972T/pt unknown
- 2017-04-14 EP EP20160781.9A patent/EP3693369A3/en not_active Withdrawn
- 2017-04-14 DK DK17781931.5T patent/DK3442972T3/da active
- 2017-04-14 ES ES17781931T patent/ES2793239T3/es active Active
- 2017-04-14 RU RU2018140061A patent/RU2741808C2/ru active
- 2017-04-14 TW TW111113671A patent/TW202304907A/zh unknown
- 2017-04-14 KR KR1020187030341A patent/KR102250415B1/ko active IP Right Grant
- 2017-04-14 RS RS20200588A patent/RS60302B1/sr unknown
- 2017-04-14 EP EP17781931.5A patent/EP3442972B1/en active Active
- 2017-04-14 HU HUE17781931A patent/HUE050217T2/hu unknown
- 2017-04-14 MA MA052814A patent/MA52814A/fr unknown
- 2017-04-14 JP JP2018545668A patent/JP6978424B2/ja active Active
- 2017-04-14 CN CN201780023689.1A patent/CN109071534B/zh active Active
- 2017-04-17 AR ARP170100968A patent/AR108207A1/es not_active Application Discontinuation
- 2017-04-18 UY UY0001037205A patent/UY37205A/es not_active Application Discontinuation
-
2018
- 2018-09-04 IL IL261586A patent/IL261586B/en active IP Right Grant
- 2018-09-07 PH PH12018501920A patent/PH12018501920A1/en unknown
- 2018-10-12 CL CL2018002924A patent/CL2018002924A1/es unknown
- 2018-10-12 DO DO2018000227A patent/DOP2018000227A/es unknown
- 2018-10-16 CO CONC2018/0011064A patent/CO2018011064A2/es unknown
- 2018-11-08 EC ECSENADI201883519A patent/ECSP18083519A/es unknown
-
2020
- 2020-04-27 US US16/858,930 patent/US20200255426A1/en not_active Abandoned
- 2020-05-06 HR HRP20200728TT patent/HRP20200728T1/hr unknown
- 2020-05-22 CY CY20201100494T patent/CY1123025T1/el unknown
- 2020-12-14 ME MEP-2020-128A patent/ME03759B/me unknown
-
2021
- 2021-01-08 AU AU2021200101A patent/AU2021200101A1/en not_active Abandoned
- 2021-02-24 US US17/183,832 patent/US20220017511A1/en not_active Abandoned
- 2021-11-10 JP JP2021183089A patent/JP2022024026A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018071216A2 (pt) | inibidores de bromodomínios | |
UY39630A (es) | Inhibidores de bromodominios | |
CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
BR112015022674A2 (pt) | inibidores de bromodomínio | |
BR112015022551A2 (pt) | inibidores de amido pirrol | |
BR112015032710A2 (pt) | inibidores de bromodomínio | |
BR112015022861A2 (pt) | inibidores de bromodomínio | |
BR112015022391A2 (pt) | inibidores de domínio bromo tetracíclico | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
BR112018007811A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
BR112015023356A2 (pt) | inibidores de quinase pirrol[2,3-b]piridina cdk9 | |
BR112019007631A2 (pt) | inibidores de bromodomínios | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
BR112019007591A2 (pt) | inibidores de bromodomínios | |
BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |